Press Releases March 27, 2026 04:05 PM

SPAR Group, Inc. Announces Timing of Fiscal 2025 Fourth Quarter and Full Year Results Conference Call

SPAR Group sets date for Q4 and full fiscal 2025 earnings release and investor conference call.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
SGRP

SPAR Group, Inc., a merchandising and marketing services provider in the US and Canada, announced it will release its fourth quarter and full fiscal year 2025 financial results on March 31, 2026, before the market opens. The company will host a conference call featuring its CEO and CFO to discuss the results and answer investor questions.

SPAR Group, Inc. Announces Timing of Fiscal 2025 Fourth Quarter and Full Year Results Conference Call
SGRP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SPAR Group plans to release fiscal Q4 and full year 2025 results on March 31, 2026, before market open.
  • A conference call with CEO and CFO will be held at 9 am ET on the same day to review results and engage with investors.
  • SPAR Group specializes in merchandising, marketing, and distribution solutions for retailers and brands across the US and Canada, impacting retail and marketing services sectors.

CHARLOTTE, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR”, “SPAR Group” or the “Company”), an innovative services company offering comprehensive merchandising, marketing and distribution solutions to retailers and brands throughout the United States and Canada, today announces that it will release its 2025 fourth quarter and fiscal year results on Tuesday, March 31, 2026, before the market opens. In conjunction with the release, a conference call will be hosted by William Linnane, Chief Executive Officer, and Steve Hennen, Chief Financial Officer, at 9am ET on the same day. If you would like to submit questions for management to address during the hosted call, please email Sandy Martin ([email protected]) from Three Part Advisors.

By Phone:Dial 1-833-630-1542, or 1-412-317-1821 if calling from an International number, at least 10 minutes before the call, and ask to be joined into the SPAR Group call. A replay will be available through April 7th by dialing 1-855-669-9658 and using the conference ID: 1914409#.  By Webcast:Connect to the webcast via the Events and Presentations page of SPAR Group’s Investor Relations website at https://investors.sparinc.com/events-and-presentations. Please log in at least 10 minutes in advance to register and download any necessary software. A replay will be available shortly after the call.  

About SPAR Group, Inc.

SPAR Group is an innovative services company offering comprehensive merchandising, marketing, and distribution solutions to retailers and brands throughout the United States and Canada. SPAR Group provides the resources and analytics that improve brand experiences and transform retail spaces. The company offers a unique combination of scale and flexibility with a passion for client results that separates us from the competition. For more information, please visit the SPAR Group’s website at http://www.sparinc.com.

Investor Relations Contact:
Three Part Advisors, LLC
Sandy Martin or Phillip Kupper
[email protected]; [email protected]
214-616-2207


Risks

  • Financial results may not meet market expectations, potentially impacting the stock price negatively.
  • Economic conditions affecting retail and marketing sectors could influence company performance and investor sentiment.
  • Uncertainties surrounding the company's ability to maintain growth and competitive advantages in a dynamic retail environment.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026